February 26, 2015

Not intended for U.S. and UK Media - Treatment of visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO):

Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion

Berlin, February 26, 2015 - Bayer HealthCare announced today that EYLEA®
(aflibercept solution for injection into the eye) has been approved by the
European Commission for the treatment of patients with visual impairment due to
macular edema secondary to retinal vein occlusion (RVO). This new indication
includes macular edema following branch retinal vein occlusion (BRVO) in
addition to the previously-approved indication of macular edema secondary to
central retinal vein occlusion in adults (CRVO). The recommended treatment
approach is to initiate therapy with one injection per month until maximum
visual acuity is achieved and/or there are no signs of disease activity.
Treatment may then be continued with a "treat and extend" regimen with
gradually increased treatment intervals to maintain stable visual and/or
anatomic outcomes.

"RVO is a chronic disease that requires early and ongoing management to obtain
the best possible vision, which is critical as many patients are still of
working-age," said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive
Committee and Head of Global Development. "This new therapeutic approach allows
physicians to individualize therapy for each patient, maximizing time between
treatments. This reduces the treatment burden on patients, physicians and their
clinics."

The approval is based on positive results from the double-masked, randomized,
active-controlled phase 3 VIBRANT study in patients with visual impairment due
to macular edema secondary to BRVO. The primary endpoint was the proportion of
subjects who gained at least 15 letters in best corrected visual acuity (BCVA)
from baseline at week 24, as measured on the Early Treatment Diabetic
Retinopathy Scale (ETDRS) eye chart, a standard chart used in research to
measure visual acuity. More than half of the patients who were treated with
aflibercept solution for injection gained at least three lines of vision.

About Retinal Vein Occlusion

Retinal vein occlusion (RVO) includes branch retinal vein occlusion (BRVO) and
central retinal vein occlusion (CRVO). RVO is a chronic eye condition that can
lead to sudden vision loss and is second only to diabetic retinopathy as the
most frequent cause of visual loss from diseases affecting the blood vessels of
the retina. While each patient experiences RVO differently, all patients are at
risk for vision loss which can impact their ability to participate in everyday
activities and may cause significant financial burden to patients, their
families as well as broader society. RVO has a significant global impact with
an estimated 16.4 million people affected worldwide, including around 13.9
million with BRVO and 2.5 million with CRVO.

RVO is the result of a blockage in a blood vessel of the retina, the light
sensitive part of the eye. In CRVO, the blockage occurs in the main retinal
vein at the optic nerve. In BRVO, the blockage occurs in one of the branch
retinal veins. If a blockage in any of the retinal veins (central or branch) is
not resolved, it can result in a number of complications. The most common
reason for vision impairment in patients with RVO is macular edema, swelling of
the macula, which is the central portion of the retina responsible for seeing
fine details.

About VEGF and EYLEA® (aflibercept solution for injection into the eye)

Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in
the body. Its normal role in a healthy organism is to trigger formation of new
blood vessels (angiogenesis) supporting the growth of the body's tissues and
organs. It is also associated with the growth of abnormal new blood vessels in
the eye, which exhibit abnormal increased permeability that leads to edema.

Aflibercept solution for injection is a recombinant fusion protein, consisting
of portions of human VEGF receptors 1 and 2 extracellular domains fused to the
Fc portion of human IgG1 and formulated as an iso-osmotic solution for
intravitreal administration. Aflibercept acts as a soluble decoy receptor that
binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the
binding and activation of their cognate VEGF receptors.

Aflibercept solution for injection into the eye has been approved under the
brand name EYLEA® in more than 80 countries for the treatment of patients with
neovascular age-related macular degeneration (wet AMD) and around 40 countries
for the treatment of visual impairment due to macular edema secondary to
central retinal vein occlusion. EYLEA is also approved for the treatment of
diabetic macular edema (DME) in over 40 countries. Over three million doses of
EYLEA have been administered since launch worldwide. In Japan, EYLEA has been
additionally approved for the treatment of myopic choroidal neovascularization
and an application for marketing authorization has also been submitted for the
treatment of macular edema secondary to BRVO. In the U.S., EYLEA is already
approved for the treatment of RVO.

Bayer HealthCare and Regeneron Pharmaceuticals, Inc. are collaborating on the
global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in
the U.S. Bayer HealthCare licensed the exclusive marketing rights outside the
U.S., where the companies share equally the profits from sales of EYLEA, except
for Japan where Regeneron receives a percentage of net sales.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 20,0 billion (2014), is one of the world's
leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global activities
of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals
divisions. Bayer HealthCare's aim is to discover, develop, manufacture and
market products that will improve human and animal health worldwide. Bayer
HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is
represented in more than 100 countries. More information is available at
www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare


Find more information at www.bayerpharma.com.


Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.